Risk factors and comorbidities for psoriatic arthritis. Literature review
DOI:
https://doi.org/10.12775/JEHS.2024.68.49913Keywords
Psoriatic arthritis, cardiovascular risk, IBD, NAFLD, lifestyle modification, metabolic syndrome, obesity, seronegative spondyloarthropathiesAbstract
Introduction:
Psoriatic arthritis is a chronic disease involving peripheral arthritis, spondylitis, dactylitis (inflammation of the whole digit) and enthesitis. It is a disease equally prevalent in both genders. Psoriatic arthritis coexists with several conditions, including metabolic syndrome, obesity, cardiovascular disease, inflammatory bowel disease, and liver disease. The reciprocal effects of comorbidities with psoriatic arthritis are demonstrated by recent research. There are several risk factors associated with the condition that might hasten or worsen its symptoms.
Aim of the Study:
The purpose of this paper is to present a thorough analysis of the research that has been done on comorbidities and risk factors for psoriatic arthritis. With an emphasis on changeable elements that might impact the disease's progression, the goal is to illustrate the multifaceted nature of psoriatic arthritis. The intention is also to highlight comorbidities that need to be considered while treating a patient with the illness.
Materials and methods:
An analysis of papers available in PubMed and Google Scholar was performed using the following key words: psoriatic arthritis, psoriatic arthritis and lifestyle, psoriatic arthritis and comorbidities, psoriatic arthritis and cardiovascular risk, psoriatic arthritis and gastrointestinal diseases, psoriatic arthritis and physical activity, psoriatic arthritis and diet, psoriatic arthritis and alcohol, psoriatic arthritis and smoking.
Conclusions:
Psoriatic arthritis is a chronic disease that affects many areas of patients' lives. It is critical to consider the connections that exist between this illness and other comorbidities. In order to provide a patient with this ailment with the best care possible, variables that might exacerbate the illness's progression must also be taken into consideration. Patients' mental health should get particular attention, and lifestyle modifications should be promoted.
References
Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020 Mar 1;59(Suppl 1):i37-i46. doi: 10.1093/rheumatology/kez383.
Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res. 2019 Sep 20;8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1.
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017 Feb;17(1):65-70. doi: 10.7861/clinmedicine.17-1-65.
Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013.
Gossec, L.; Baraliakos, X.; Kerschbaumer, A.; de Wit, M.; McInnes, I.; Dougados, M.; Primdahl, J.; McGonagle, D.G.; Aletaha, D.; Balanescu, A.; et al. EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update. Ann. Rheum. Dis. 2020, 79, S700–S712.
Ana Belén Azuaga, Julio Ramírez , Juan D. Cañete. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023 Mar 3;24(5):4901. doi: 10.3390/ijms24054901.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)–an analysis of 220 patients. Q J Med 1987;62:127–41.
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017 Feb;17(1):65-70. doi: 10.7861/clinmedicine.17-1-65.
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018 May;14(5):405-417. doi: 10.1080/1744666X.2018.1468252. Epub 2018 Apr 30.
Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121–45.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 54(8):2665–73. 10.1002/art.21972.
Porta S, Otero-Losada M, Kölliker Frers RA, Cosentino V, Kerzberg E, Capani F. Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis. Front Immunol. 2021 Feb 10;11:590749. doi: 10.3389/fimmu.2020.590749.
Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol. 2020; 214108397.
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012 Aug;71(8):1267-72. doi: 10.1136/annrheumdis-2011-201273. Epub 2012 May 5.
Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–1534.
Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013;52(1):62–67.
Kumthekar A, Ogdie A. Obesity and Psoriatic Arthritis: A Narrative Review. Rheumatol Ther. 2020 Sep;7(3):447-456. doi: 10.1007/s40744-020-00215-6. Epub 2020 Jun 3.
Ramírez J, Azuaga-Piñango AB, Celis R, Cañete JD. Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis. Front Med (Lausanne). 2021 Oct 8;8:742713. doi: 10.3389/fmed.2021.742713.
Klingberg E, Bilberg A, Björkman S, et al.. Weight loss improves disease activity in patients with Psoriatic arthritis and obesity: an Interventional study. Arthritis Res Ther 2019;21:17. 10.1186/s13075-019-1810-5.
Mathew AJ, Chandran V. Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. Rheumatol Ther. 2020 Jun;7(2):287-300. doi: 10.1007/s40744-020-00207-6. Epub 2020 Apr 22.
McDonough E,, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41:887-896.
Bandinelli F, Prignano F, Bonciani D, et al. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clin Exp Rheumatol 2013;31:318-319.
De Lorenzis E, Di Giorgio A, Natalello G, Nesci A, Tanti G, Rubortone P, Lucchetti D, Magurano MR, Di Mario C, Tolusso B, Peluso G, Santoliquido A, Gremese E. Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship? Front Med (Lausanne). 2021 Aug 27;8:669397. doi: 10.3389/fmed.2021.669397.
Georgia Lada, Hector Chinoy, Peter S. Talbot, Richard B. Warren, C. Elise Kleyn. Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). First published: 06 July 2022 https://doi.org/10.1002/ski2.149.
Duvetorp A, Østergaard M, Skov L, et al.. Quality of life and contact with Healthcare systems among patients with psoriasis and Psoriatic arthritis: results from the Nordic patient survey of psoriasis and Psoriatic. Arch Dermatol Res 2019;311:351–60. 10.1007/s00403-019-01906-z.
Toledano E, Hidalgo C, Gómez-Lechón L, Ibáñez M, Chacón CC, Martín-Vallejo J, Pastor S, Montilla C. SLEEP quality in patients with psoriatic arthritis and its relationship with disease activity and comorbidities: a cross-sectional study. Sci Rep. 2023 Dec 21;13(1):22927. doi: 10.1038/s41598-023-48723-z.
Rausch Osthoff A-K, Niedermann K, Braun J, et al.. EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 2018;77:1251–60. 10.1136/annrheumdis-2018-213585.
Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise - a review. RMD Open. 2023 Aug;9(3):e003339. doi: 10.1136/rmdopen-2023-003339.
Osman AA, Hoff M, Videm V. High physical activity in persons with psoriatic arthritis is associated with reduced visceral fat mass and percentage body fat: the Trøndelag Health study. Rheumatol Int. 2023 Sep;43(9):1685-1693. doi: 10.1007/s00296-023-05348-9. Epub 2023 Jun 5.
Nguyen UDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Ogdie A, Gelfand JM, LaValley MP, Dubreuil M, Sparks JA, Karlson EW, Choi HK. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis. 2018 Jan;77(1):119-123. doi: 10.1136/annrheumdis-2017-211625. Epub 2017 Nov 4.
Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019 Jan;15(1):41-48. doi: 10.1080/1744666X.2019.1543591. Epub 2018 Nov 6.
Wu S, Cho E, Li WQ, Han J, Qureshi AA. Alcohol intake and risk of incident psoriatic arthritis in women. J Rheumatol. 2015 May;42(5):835-40. doi: 10.3899/jrheum.140808. Epub 2015 Apr 1.
Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol (2005) 125(1):61–7. 10.1111/j.0022-202X.2005.23681.x
Degboé Y, Koch R, Zabraniecki L, Jamard B, Couture G, Ruidavets JB, Ferrieres J, Ruyssen-Witrand A, Constantin A. Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study. Front Med (Lausanne). 2022 May 19;9:785719. doi: 10.3389/fmed.2022.785719.
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.
Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, et al. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front Immunol (2018) 9:1668. 10.3389/fimmu.2018.01668.
Caso F, Chimenti MS. Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol (2020) 16: (4):409–20. 10.1080/1744666X.2020.1740593.
Kölliker Frers RA, Bisoendial RJ, Montoya SF, Kerzkerg E, Castilla R, Takc PP, et al. Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metab Endocr (2015) 6:43–54. 10.1016/j.ijcme.2015.01.005.
Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatol (Oxford) (2013) 52(1):62–7. 10.1093/rheumatology/kes242.
Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673–685. doi: 10.1016/j.cytogfr.2015.04.003.
Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31(4):711–715. doi: 10.1007/s10067-011-1892-1.
Tam LS, Tomlinson B, Chu TTW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - The role of inflammation. Rheumatology. 2008;47(5):718–723. doi: 10.1093/rheumatology/ken090
Aljohani R. Metabolic Syndrome and Its Components in Psoriatic Arthritis. Open Access Rheumatol. 2022 Feb 17;14:7-16. doi: 10.2147/OARRR.S347797.
Wang CR, Tsai HW. Seronegative spondyloarthropathy-associated inflammatory bowel disease. World J Gastroenterol. 2023 Jan 21;29(3):450-468. doi: 10.3748/wjg.v29.i3.450.
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317. doi: 10.1038/nature10209.
Yousaf A, Raiker R, Davis SM, Gayam S, Zinn Z. Association between psoriasis, psoriatic arthritis and gastrointestinal disease : An exploratory nationwide inpatient sample analysis. Wien Klin Wochenschr. 2021 Jun;133(11-12):586-593. doi: 10.1007/s00508-020-01740-8. Epub 2020 Sep 23.
Freuer D, Linseisen J, Meisinger C. Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study. JAMA Dermatol. 2022 Sep 14;158(11):1262–8. doi: 10.1001/jamadermatol.2022.3682. Epub ahead of print.
Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from south India. Australas J Dermatol (2012) 53:190–7. doi: 10.1111/j.1440-0960.2012.00905.x.
Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, et al.. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther (2015) 41:293–300. doi: 10.1111/apt.13042.
Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges (2021) 19(4):517–28. doi: 10.1111/ddg.14425.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Pich-Czekierda, Zuzanna Kotowicz, Patrycja Proszowska, Adrianna Orzeł , Daria Sieniawska, Magda Madoń, Julia Sieniawska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 300
Number of citations: 0
